Tempest secures exclusive option to license Senlang's CD7-targeted in vivo CAR-T platform

Tempest Therapeutics, Inc.

Option exercisable within 4 months for ~$447,000 fee; exclusive license for ex-Greater China rights.
Post-exercise fees: annual maintenance $10M-$14M over first 3 years, 6% net-sales royalty, sublicense revenue share.
Lead BCMA/GPRC5D dual-targeting candidate in Phase 1 for relapsed/refractory multiple myeloma; early in vivo CAR-T generation observed.
As of Aug 25, 2026, no Grade 3+ CRS or ICANS; safety profile supports continued dose escalation.
Agreement complements Tempest's existing LNP platform; expands portfolio to hematologic and autoimmune indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.